Fusion Antibodies (LON:FAB) Stock Price Down 0.8% – Here’s What Happened

by · The Cerbat Gem

Shares of Fusion Antibodies plc (LON:FAB – Get Free Report) dropped 0.8% during mid-day trading on Tuesday . The stock traded as low as GBX 14.50 and last traded at GBX 14.64. Approximately 375,892 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 616,346 shares. The stock had previously closed at GBX 14.75.

Fusion Antibodies Stock Down 0.8%

The business has a 50-day simple moving average of GBX 14.06 and a two-hundred day simple moving average of GBX 13.52. The company has a market capitalization of £16.63 million, a price-to-earnings ratio of -9.76 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87.

Fusion Antibodies (LON:FAB – Get Free Report) last released its quarterly earnings results on Monday, November 24th. The company reported GBX (0.50) EPS for the quarter. Fusion Antibodies had a negative return on equity of 137.11% and a negative net margin of 195.95%. As a group, equities analysts predict that Fusion Antibodies plc will post -129.9999875 EPS for the current year.

About Fusion Antibodies

(Get Free Report)

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.

Featured Stories